GlassScriptPhysician profile
Mario Mangas
NPI 1205822251
$7,101.35
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,109 · 2020: $3,311 · 2021: $2,681.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $5,761.23 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $453.90 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.15 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $189.41 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $91.28 | 2021 | |
| Mylan Specialty L.P. | $83.82 | 2020-2021 | |
| Advanced Respiratory, INC | $78.31 | 2021 | |
| Genzyme Corporation | $66.77 | 2021 | |
| Sunovion Pharmaceuticals INC. | $46.43 | 2020-2021 | |
| Philips North America LLC | $37.79 | 2021 | |
| Covidien LP | $24.64 | 2019 | |
| United Therapeutics Corporation | $22.24 | 2021 | |
| Ambu INC. | $20.30 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $12.05 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.03 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Mangas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.